These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33974312)

  • 1. Editorial for "Serum Ceruloplasmin Depletion is Associated With the Widespread Accumulation of Brain Iron in Parkinson's Disease".
    Gupta RK
    J Magn Reson Imaging; 2021 Oct; 54(4):1107. PubMed ID: 33974312
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum Ceruloplasmin Depletion is Associated With Magnetic Resonance Evidence of Widespread Accumulation of Brain Iron in Parkinson's Disease.
    Guan X; Bai X; Zhou C; Guo T; Wu J; Gu L; Gao T; Wang X; Wei H; Zhang Y; Xuan M; Gu Q; Huang P; Liu C; Zhang B; Pu J; Song Z; Yan Y; Xu X; Zhang M
    J Magn Reson Imaging; 2021 Oct; 54(4):1098-1106. PubMed ID: 33949744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.
    Jin L; Wang J; Jin H; Fei G; Zhang Y; Chen W; Zhao L; Zhao N; Sun X; Zeng M; Zhong C
    Eur J Neurol; 2012 Jul; 19(7):969-76. PubMed ID: 22288465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.
    Grolez G; Moreau C; Sablonnière B; Garçon G; Devedjian JC; Meguig S; Gelé P; Delmaire C; Bordet R; Defebvre L; Cabantchik IZ; Devos D
    BMC Neurol; 2015 May; 15():74. PubMed ID: 25943368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional relevance of ceruloplasmin mutations in Parkinson's disease.
    Hochstrasser H; Tomiuk J; Walter U; Behnke S; Spiegel J; Krüger R; Becker G; Riess O; Berg D
    FASEB J; 2005 Nov; 19(13):1851-3. PubMed ID: 16150804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplanted Neural Stem Cells: Playing a Neuroprotective Role by Ceruloplasmin in the Substantia Nigra of PD Model Rats?
    Xiao JJ; Yin M; Wang ZJ; Wang XP
    Oxid Med Cell Longev; 2015; 2015():618631. PubMed ID: 26146528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention.
    Olivieri S; Conti A; Iannaccone S; Cannistraci CV; Campanella A; Barbariga M; Codazzi F; Pelizzoni I; Magnani G; Pesca M; Franciotta D; Cappa SF; Alessio M
    J Neurosci; 2011 Dec; 31(50):18568-77. PubMed ID: 22171055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ceruloplasmin (Cp) and iron in connection with Parkinson's disease (PD) and Alzheimer's disease (AD)].
    Johannesson T; Kristinsson J; Torsdottir G; Snaedal J
    Laeknabladid; 2012 Oct; 98(10):531-7. PubMed ID: 23043066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceruloplasmin in Parkinson's disease and the nonmotor symptoms.
    Zhao X; Shao Z; Zhang Y; Liu F; Liu Z; Liu Z
    Brain Behav; 2018 Jun; 8(6):e00995. PubMed ID: 29733522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.
    Ayton S; Lei P; Duce JA; Wong BX; Sedjahtera A; Adlard PA; Bush AI; Finkelstein DI
    Ann Neurol; 2013 Apr; 73(4):554-9. PubMed ID: 23424051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
    Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
    J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
    Dexter DT; Wells FR; Lees AJ; Agid F; Agid Y; Jenner P; Marsden CD
    J Neurochem; 1989 Jun; 52(6):1830-6. PubMed ID: 2723638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.
    Guan X; Xu X; Zhang M
    Neurosci Bull; 2017 Oct; 33(5):561-567. PubMed ID: 28516282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease.
    Hochstrasser H; Bauer P; Walter U; Behnke S; Spiegel J; Csoti I; Zeiler B; Bornemann A; Pahnke J; Becker G; Riess O; Berg D
    Neurology; 2004 Nov; 63(10):1912-7. PubMed ID: 15557511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease.
    Liddell JR; White AR
    Neurochem Int; 2018 Jul; 117():126-138. PubMed ID: 28577988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered systemic iron metabolism in Parkinson's disease.
    Logroscino G; Marder K; Graziano J; Freyer G; Slavkovich V; LoIacono N; Cote L; Mayeux R
    Neurology; 1997 Sep; 49(3):714-7. PubMed ID: 9305329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceruloplasmin is Involved in the Nigral Iron Accumulation of 6-OHDA-Lesioned Rats.
    Wang J; Bi M; Xie J
    Cell Mol Neurobiol; 2015 Jul; 35(5):661-8. PubMed ID: 25656940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.